- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
2nd Japan-India Medical Products Regulation Symposium held in Tokyo. | 24 April, 2017
Dr. Gurpreet Sandhu, CEO of Reva Pharma delivered lecture on “Healthcare & Pharmaceutical Trends in India†at the 2nd Japan-India Medical Products Regulation Symposium held in Tokyo on 24th of April, 2017. The symposium was conducted for 2 days with participation from Ministry of Health (Japan & India), Drug Regulators of both nations, Trade Associations and Industry leaders.
The symposium shared the best practices in the regulation of pharmaceuticals and medical devices in both India and Japan and also discussed the international regulatory harmonization and cooperation. The symposium aims to improve the level of regulatory systems as well as facilitate the regulatory compliance for the industry.